Language: BG BG
← Back to results
Not yet recruiting Not applicable NCT07546357

AIManage Using an AI-driven CDS and Chatbot

No applicable phase (e.g. observational)
Conditions: Diabetes Obesity Medication Side Effects

Sponsor: NYU Langone Health

trial.available_in: БГ
Overview
The objective of this project is to define and test the GenAI-powered Clinical Decision Support (CDS) tool, AIManage, providing a broad range of incretin mimetic medication management services to optimize dose titrations. The study will take place across primary care and obesity medicine clinics at NYUH. The study is currently conducting formative data collection for tool refinement (Phase 1). Once completed, a cluster randomized controlled trial of the AIManage tool will be undertaken (Phase 2).
Who can participate
Inclusion Criteria: Provider Eligibility Criteria (Phase 1) * Primary or bariatric care provider (MD/DO, NP) practicing at the participating NYULH clinics, * Provide care to at least 5 patients prescribed an IMM. Patient Eligibility Criteria (Phase 1) * (Phase 1) Currently taking an IMM or have taken an IMM in the past 6 months; * Fluency in English or Spanish; * Be willing to send/receive text messages; and * Be \> 18 years of age. Exclusion Criteria: Provider Exclusion Criteria (Phase 1) • Refuse to participate Patient Exclusion Criteria (Phase 1) • Refuse or are unable to provide informed consent;
Interventions
AIManage
OTHER
Locations 1
United States (1)
NYU Langone Health
New York , New York
Technical details
Status
Not yet recruiting
Phase
Not applicable
Study type
INTERVENTIONAL
Sex
Male and female
Minimum age
18 Years
Healthy volunteers
No
Start date
01.06.2026
Completion date
30.03.2029
Registry ID
NCT07546357
Source
clinicaltrials.gov
trial.inquiry_btn

Information is automatically extracted from ClinicalTrials.gov. Consult your doctor before taking action.